Open an account

Precipio

PRPO · NASDAQ

$21.72−$0.17 (−0.78%)TodayMarket closed ·
Prev close $21.89

About PRPO

Precipio, Inc.is a cancer diagnostics and reagent technology company, which provides diagnostic products and services to the oncology market. The company is headquartered in New Haven, Connecticut and currently employs 61 full-time employees. The company went IPO on 2000-07-18. The Company’s technologies include HemeScreen and IV-Cell. The HemeScreen panels test for the presence of various mutations. In developing HemeScreen, it focused on improving the economics of providing blood cancer diagnostic tests and reducing laboratory technician time consumed in the testing process. Its technology enables testing to be completed in one rapid scanning process. IV-Cell is a cell culture media that addresses the problem of diagnostic mistakes through the process of selective culturing. IV-Cell is a universal media that enables simultaneous culturing of all four hematopoietic cell lineages. Its product category includes Molecular Kits and IV-Cell Cytogenetics Media. The Molecular Kits include Quantitative MPN Panel, ABL1 Resistance Panel, and others. The Company’s laboratory and research and development (R&D) facilities are located in New Haven, Connecticut and Omaha, Nebraska.

Employees
61
Headquarters
New Haven, Connecticut
Listed
Jul 18, 2000
Sector
Health Care
Industry
Health Care Providers & Services
Website
precipiodx.com

PRPO key statistics

Market cap
38.88M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
52.98K
Volume
26.64K
Open price
$21.90
High today
$22.52
Low today
$21.72
52 Week high
$33.63
52 Week low
$18.00

Precipio (PRPO) at a glance

Precipio (PRPO) last traded at $21.72, with a market cap of 38.88M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $21.72 and $22.52. The current price is 0.0% above the day's low and 3.5% below its high.

Volume so far is 26.64K shares, below the average of 52.98K shares a day.

Over the past year Precipio has ranged from $18.00 to $33.63, and now sits 24% of the way up that range.

Precipio met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY25 it reported $0.05 per share against an estimate of $0.00.

PRPO earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 11.9% on average.

  1. Q2 FY21: reported -$2.80 per share against an estimate of -$2.04
  2. Q4 FY21: reported -$1.80 per share against an estimate of -$1.63
  3. Q3 FY22: reported -$2.80 per share against an estimate of -$0.816
  4. Q4 FY22: reported -$2.00 per share against an estimate of -$2.86
  5. Q1 FY23: reported -$2.60 per share against an estimate of -$2.65
  6. Q2 FY23: reported -$1.80 per share against an estimate of -$2.04
  7. Q3 FY23: reported -$1.04 per share against an estimate of -$1.23
  8. Q2 FY25: reported $0.05 per share against an estimate of $0.00

Similar companies

Companies in the same industry as Precipio

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.